BEIJING & VANCOUVER, British Columbia--(BUSINESS WIRE)--Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in China, today announced an exclusive license with privately held Primary Peptides, Inc., to develop and commercialise innovative products targeting PTEN nuclear translocation for the treatment of stroke.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
